Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.
Identifieur interne : 000939 ( PubMed/Checkpoint ); précédent : 000938; suivant : 000940Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.
Auteurs : Madeleine E. Sharp [Canada] ; Jayalakshmi Viswanathan ; Martin J. Mckeown ; Silke Appel-Cresswell ; A Jon Stoessl ; Jason J S. BartonSource :
- Neuropsychologia [ 1873-3514 ] ; 2013.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (pharmacology), Antiparkinson Agents (therapeutic use), Case-Control Studies, Decision Making (drug effects), Decision Making (physiology), Disruptive, Impulse Control, and Conduct Disorders (etiology), Female, Games, Experimental, Humans, Levodopa (pharmacology), Levodopa (therapeutic use), Male, Middle Aged, Parkinson Disease (complications), Parkinson Disease (drug therapy), Parkinson Disease (psychology), Probability, Psychometrics, Risk-Taking.
- MESH :
- chemical , pharmacology : Antiparkinson Agents, Levodopa.
- chemical , therapeutic use : Antiparkinson Agents, Levodopa.
- complications : Parkinson Disease.
- drug effects : Decision Making.
- drug therapy : Parkinson Disease.
- etiology : Disruptive, Impulse Control, and Conduct Disorders.
- physiology : Decision Making.
- psychology : Parkinson Disease.
- Aged, Case-Control Studies, Female, Games, Experimental, Humans, Male, Middle Aged, Probability, Psychometrics, Risk-Taking.
Abstract
Unmedicated Parkinson's disease patients tend to be risk-averse while dopaminergic treatment causes a tendency to take risks. While dopamine agonists may result in clinically apparent impulse control disorders, treatment with levodopa also causes shift in behaviour associated with an enhanced response to rewards. Two important determinants in decision-making are how subjects perceive the magnitude and probability of outcomes. Our objective was to determine if patients with Parkinson's disease on or off levodopa showed differences in their perception of value when making decisions under risk.
DOI: 10.1016/j.neuropsychologia.2013.08.008
PubMed: 23954375
Affiliations:
Links toward previous steps (curation, corpus...)
Links to Exploration step
pubmed:23954375Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.</title><author><name sortKey="Sharp, Madeleine E" sort="Sharp, Madeleine E" uniqKey="Sharp M" first="Madeleine E" last="Sharp">Madeleine E. Sharp</name><affiliation wicri:level="1"><nlm:affiliation>Human Vision and Eye Movement Laboratory, Department of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Electronic address: madeleinesharp@gmail.com.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Vision and Eye Movement Laboratory, Department of Medicine (Neurology), University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Viswanathan, Jayalakshmi" sort="Viswanathan, Jayalakshmi" uniqKey="Viswanathan J" first="Jayalakshmi" last="Viswanathan">Jayalakshmi Viswanathan</name></author><author><name sortKey="Mckeown, Martin J" sort="Mckeown, Martin J" uniqKey="Mckeown M" first="Martin J" last="Mckeown">Martin J. Mckeown</name></author><author><name sortKey="Appel Cresswell, Silke" sort="Appel Cresswell, Silke" uniqKey="Appel Cresswell S" first="Silke" last="Appel-Cresswell">Silke Appel-Cresswell</name></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name></author><author><name sortKey="Barton, Jason J S" sort="Barton, Jason J S" uniqKey="Barton J" first="Jason J S" last="Barton">Jason J S. Barton</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23954375</idno><idno type="pmid">23954375</idno><idno type="doi">10.1016/j.neuropsychologia.2013.08.008</idno><idno type="wicri:Area/PubMed/Corpus">000845</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000845</idno><idno type="wicri:Area/PubMed/Curation">000845</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000845</idno><idno type="wicri:Area/PubMed/Checkpoint">000845</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000845</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.</title><author><name sortKey="Sharp, Madeleine E" sort="Sharp, Madeleine E" uniqKey="Sharp M" first="Madeleine E" last="Sharp">Madeleine E. Sharp</name><affiliation wicri:level="1"><nlm:affiliation>Human Vision and Eye Movement Laboratory, Department of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Electronic address: madeleinesharp@gmail.com.</nlm:affiliation><country xml:lang="fr">Canada</country><wicri:regionArea>Human Vision and Eye Movement Laboratory, Department of Medicine (Neurology), University of British Columbia, Vancouver, BC</wicri:regionArea><wicri:noRegion>BC</wicri:noRegion></affiliation></author><author><name sortKey="Viswanathan, Jayalakshmi" sort="Viswanathan, Jayalakshmi" uniqKey="Viswanathan J" first="Jayalakshmi" last="Viswanathan">Jayalakshmi Viswanathan</name></author><author><name sortKey="Mckeown, Martin J" sort="Mckeown, Martin J" uniqKey="Mckeown M" first="Martin J" last="Mckeown">Martin J. Mckeown</name></author><author><name sortKey="Appel Cresswell, Silke" sort="Appel Cresswell, Silke" uniqKey="Appel Cresswell S" first="Silke" last="Appel-Cresswell">Silke Appel-Cresswell</name></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name></author><author><name sortKey="Barton, Jason J S" sort="Barton, Jason J S" uniqKey="Barton J" first="Jason J S" last="Barton">Jason J S. Barton</name></author></analytic><series><title level="j">Neuropsychologia</title><idno type="eISSN">1873-3514</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (pharmacology)</term><term>Antiparkinson Agents (therapeutic use)</term><term>Case-Control Studies</term><term>Decision Making (drug effects)</term><term>Decision Making (physiology)</term><term>Disruptive, Impulse Control, and Conduct Disorders (etiology)</term><term>Female</term><term>Games, Experimental</term><term>Humans</term><term>Levodopa (pharmacology)</term><term>Levodopa (therapeutic use)</term><term>Male</term><term>Middle Aged</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Parkinson Disease (psychology)</term><term>Probability</term><term>Psychometrics</term><term>Risk-Taking</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antiparkinson Agents</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Decision Making</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Disruptive, Impulse Control, and Conduct Disorders</term></keywords><keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>Decision Making</term></keywords><keywords scheme="MESH" qualifier="psychology" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Case-Control Studies</term><term>Female</term><term>Games, Experimental</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Probability</term><term>Psychometrics</term><term>Risk-Taking</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Unmedicated Parkinson's disease patients tend to be risk-averse while dopaminergic treatment causes a tendency to take risks. While dopamine agonists may result in clinically apparent impulse control disorders, treatment with levodopa also causes shift in behaviour associated with an enhanced response to rewards. Two important determinants in decision-making are how subjects perceive the magnitude and probability of outcomes. Our objective was to determine if patients with Parkinson's disease on or off levodopa showed differences in their perception of value when making decisions under risk.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23954375</PMID><DateCreated><Year>2013</Year><Month>11</Month><Day>11</Day></DateCreated><DateCompleted><Year>2014</Year><Month>06</Month><Day>25</Day></DateCompleted><DateRevised><Year>2015</Year><Month>11</Month><Day>19</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-3514</ISSN><JournalIssue CitedMedium="Internet"><Volume>51</Volume><Issue>13</Issue><PubDate><Year>2013</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neuropsychologia</Title><ISOAbbreviation>Neuropsychologia</ISOAbbreviation></Journal><ArticleTitle>Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.</ArticleTitle><Pagination><MedlinePgn>2679-89</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.neuropsychologia.2013.08.008</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0028-3932(13)00269-8</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Unmedicated Parkinson's disease patients tend to be risk-averse while dopaminergic treatment causes a tendency to take risks. While dopamine agonists may result in clinically apparent impulse control disorders, treatment with levodopa also causes shift in behaviour associated with an enhanced response to rewards. Two important determinants in decision-making are how subjects perceive the magnitude and probability of outcomes. Our objective was to determine if patients with Parkinson's disease on or off levodopa showed differences in their perception of value when making decisions under risk.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">The Vancouver Gambling task presents subjects with a choice between one prospect with larger outcome and a second with higher probability. Eighteen age-matched controls and eighteen patients with Parkinson's disease before and after levodopa were tested. In the Gain Phase subjects chose between one prospect with higher probability and another with larger reward to maximize their gains. In the Loss Phase, subjects played to minimize their losses.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Patients with Parkinson's disease, on or off levodopa, were similar to controls when evaluating gains. However, in the Loss Phase before levodopa, they were more likely to avoid the prospect with lower probability but larger loss, as indicated by the steeper slope of their group psychometric function (t(24) = 2.21, p = 0.04). Modelling with prospect theory suggested that this was attributable to a 28% overestimation of the magnitude of loss, rather than an altered perception of its probability.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">While pre-medicated patients with Parkinson's disease show risk-aversion for large losses, patients on levodopa have normal perception of magnitude and probability for both loss and gain. The finding of accurate and normally biased decisions under risk in medicated patients with PD is important because it indicates that, if there is indeed anomalous risk-seeking behaviour in such a cohort, it may derive from abnormalities in components of decision making that are separate from evaluations of size and probability.</AbstractText><CopyrightInformation>© 2013 Elsevier Ltd. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sharp</LastName><ForeName>Madeleine E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Human Vision and Eye Movement Laboratory, Department of Medicine (Neurology), University of British Columbia, Vancouver, BC, Canada. Electronic address: madeleinesharp@gmail.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Viswanathan</LastName><ForeName>Jayalakshmi</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>McKeown</LastName><ForeName>Martin J</ForeName><Initials>MJ</Initials></Author><Author ValidYN="Y"><LastName>Appel-Cresswell</LastName><ForeName>Silke</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Stoessl</LastName><ForeName>A Jon</ForeName><Initials>AJ</Initials></Author><Author ValidYN="Y"><LastName>Barton</LastName><ForeName>Jason J S</ForeName><Initials>JJ</Initials></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>MOP-81270</GrantID><Agency>Canadian Institutes of Health Research</Agency><Country>Canada</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>15</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Neuropsychologia</MedlineTA><NlmUniqueID>0020713</NlmUniqueID><ISSNLinking>0028-3932</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003657" MajorTopicYN="N">Decision Making</DescriptorName><QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName><QualifierName UI="Q000502" MajorTopicYN="Y">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007174" MajorTopicYN="N">Disruptive, Impulse Control, and Conduct Disorders</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="Y">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005717" MajorTopicYN="N">Games, Experimental</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000523" MajorTopicYN="Y">psychology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011336" MajorTopicYN="Y">Probability</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011594" MajorTopicYN="N">Psychometrics</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012309" MajorTopicYN="Y">Risk-Taking</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Decision-making</Keyword><Keyword MajorTopicYN="N">Impulse control disorders</Keyword><Keyword MajorTopicYN="N">Parkinson’s disease</Keyword><Keyword MajorTopicYN="N">Prospect theory</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2013</Year><Month>03</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2013</Year><Month>07</Month><Day>24</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2013</Year><Month>08</Month><Day>08</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>20</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2014</Year><Month>6</Month><Day>26</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23954375</ArticleId><ArticleId IdType="pii">S0028-3932(13)00269-8</ArticleId><ArticleId IdType="doi">10.1016/j.neuropsychologia.2013.08.008</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Appel Cresswell, Silke" sort="Appel Cresswell, Silke" uniqKey="Appel Cresswell S" first="Silke" last="Appel-Cresswell">Silke Appel-Cresswell</name><name sortKey="Barton, Jason J S" sort="Barton, Jason J S" uniqKey="Barton J" first="Jason J S" last="Barton">Jason J S. Barton</name><name sortKey="Mckeown, Martin J" sort="Mckeown, Martin J" uniqKey="Mckeown M" first="Martin J" last="Mckeown">Martin J. Mckeown</name><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A Jon" last="Stoessl">A Jon Stoessl</name><name sortKey="Viswanathan, Jayalakshmi" sort="Viswanathan, Jayalakshmi" uniqKey="Viswanathan J" first="Jayalakshmi" last="Viswanathan">Jayalakshmi Viswanathan</name></noCountry><country name="Canada"><noRegion><name sortKey="Sharp, Madeleine E" sort="Sharp, Madeleine E" uniqKey="Sharp M" first="Madeleine E" last="Sharp">Madeleine E. Sharp</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Checkpoint
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000939 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd -nk 000939 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Checkpoint
|type= RBID
|clé= pubmed:23954375
|texte= Decisions under risk in Parkinson's disease: preserved evaluation of probability and magnitude.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Checkpoint/RBID.i -Sk "pubmed:23954375" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Checkpoint/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |